טוען...
Defining and understanding adaptive resistance in cancer immunotherapy
Despite the unprecedented tumor regression and long-term survival benefit observed with anti-Programmed Death (PD) (anti-PD-1 or anti-B7-homolog 1 (B7-H1)) therapy in patients with advanced cancers, a large portion of patients do not benefit from such treatment and a fraction of responders relapse....
שמור ב:
| הוצא לאור ב: | Trends Immunol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6066429/ https://ncbi.nlm.nih.gov/pubmed/29802087 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.it.2018.05.001 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|